Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression

David A. Jacobsohn*, Michael R. Loken, Mingwei Fei, Alexia Adams, Lisa Eidenschink Brodersen, Brent R. Logan, Kwang Woo Ahn, Bronwen E. Shaw, Morris Kletzel, Marie Olszewski, Sana Khan, Soheil Meshinchi, Amy Keating, Andrew Harris, Pierre Teira, Reggie E Duerst, Steven P. Margossian, Paul L. Martin, Aleksandra Petrovic, Christopher C. DvorakEneida R. Nemecek, Michael W. Boyer, Allen R. Chen, Jeffrey H. Davis, Shalini Shenoy, Sureyya Savasan, Michelle P. Hudspeth, Roberta H. Adams, Victor A. Lewis, Albert Kheradpour, Kimberly A. Kasow, Alfred P. Gillio, Ann E. Haight, Monica Bhatia, Barbara J. Bambach, Hilary L. Haines, Troy C. Quigg, Robert J. Greiner, Julie An M. Talano, David C. Delgado, Alexandra Cheerva, Madhu Gowda, Sanjay Ahuja, Mehmet Ozkaynak, David Mitchell, Kirk R. Schultz, Terry J. Fry, David M. Loeb, Michael A. Pulsipher

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Fingerprint Dive into the research topics of 'Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression'. Together they form a unique fingerprint.

Medicine & Life Sciences